Tesla (NASDAQ:TSLA) will be under the Street’s microscope today with the EV giant slated to release 4Q24 results after the ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Goldman Sachs increased its price target for Meta Platforms Inc. (NASDAQ: NASDAQ:META) shares, raising it from $688.00 to $765.00. Currently trading at $676.49, the stock has delivered an impressive ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Goldman is expected to ...

In the fast-paced world of investing, staying ahead requires good ideas and timely decisions. This article highlights five ...

The fact that multiple The Goldman Sachs Group, Inc. insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When ...

AbbVie is one of the better pharmaceutical stocks on the scene, buttressed by a strong product lineup and a promising ...

Analyst raises earnings estimates and price target for Goldman Sachs ... the previous quarter and 36% year-over-year. While the stock remains pricey relative to historical multiples at 1.92x ...